Abstracts tagged "ANCA"

Abstract Number: 2621 • 2019 ACR/ARP Annual Meeting
Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis
Linda Vergel Orduz¹, Alejandro Brigante ², Diego Marino ³, Natalia Perrotta ³, Romina Hassan ⁴, Gisele Verna ⁵, Adriana Hamaui ⁶, Eduardo Kerzberg ⁷ and Diana Dubinsky ⁶, ¹Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, ²Sanatorio Güemes, Servicio de Medicina Interna – Reumatología, Francisco Acuña de Figueroa 1240, C1180AAD, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ³Hospital de Clínicas José de San Martín, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital Ramos Mejía, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁶Sanatorio Güemes, Buenos Aires, Argentina, ⁷Hospital Ramos Mejia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: In associated ANCA vasculitis (AAV), rapidly progressive glomerulonephritis (GN) is one of the most serious complications. In 40% of cases they progress to chronic…
Abstract Number: 1662 • 2019 ACR/ARP Annual Meeting
Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?
Matthias Papo¹, Renato A. Sinico ², Vítor Teixeira ³, Maria-Letizia Urban ⁴, Juliane Mahrhold ⁵, Francesco Locatelli ⁶, Giulia Cassone ⁷, Franco Schiavon ⁸, Benjamin Seeliger ⁹, Thomas Neumann ¹⁰, Claus Kroegel ¹¹, Matthieu Groh ¹², Chiara Marvisi ¹³, Maxime Samson ¹⁴, Thomas Barba ¹⁵, David Jayne ¹⁶, Bernhard Hellmich ⁵, Sara Monti ¹⁷, Carlomaurizio Montecucco ⁶, Carlo Salvarani ¹⁸, Jean-Emmanuel Kahn ¹², Cécile-Audrey Durel ¹⁵, Loic Guillevin ¹⁹, Giacomo Emmi ⁴, Augusto Vaglio ²⁰ and Benjamin Terrier ¹⁹, ¹Department of Internal Medicine, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Paris, France, ²Department of Medicine and Surgery, Università degli Studi di Milano - Bicocca , Italy, Milan, Italy, ³Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Lisbon, Portugal., Lisbon, Portugal, ⁴Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy, Florence, Italy, ⁵Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ⁶Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁷Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. Rheumatology Unit, IRCCS Arcispedale Santa Maria Nuova, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Modena and Reggio Emilia, Italy, ⁸Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, Padova, Italy, ⁹Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, Hannover, Germany, ¹⁰Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ¹¹Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, Jena, Germany, ¹²Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, Suresnes, France, ¹³Nephrology Unit, Parma University Hospital, Parma, Italy, Parma, Italy, ¹⁴CHU Dijon, Dijon, France, ¹⁵Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹⁶Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ¹⁷University of Pavia, Pavia, Italy, ¹⁸Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ²⁰Nephrology Unit, Parma University Hospital, Parma, Italy, Nephrology Unit, Parma University Hospital, Parma, Italy, Italy
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss) is a small-vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Only a third of EGPA…
Abstract Number: 2625 • 2019 ACR/ARP Annual Meeting
Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement
Gelsomina Alle¹, John Jaramillo Gallego ², Marina Scolnik ³, Valeria Scaglioni ², Martin Brom ⁴, Carlos Varela ⁵, Gustavo Greloni ⁵ and Enrique Soriano ⁶, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Nephrology Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The aim of this study was to evaluate the predictors of advanced chronic kidney disease (ACKD) in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis…
Abstract Number: 1664 • 2019 ACR/ARP Annual Meeting
Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial
Pierre Charles¹, Agnes Dechartres ², Benjamin Terrier ³, Pascal Cohen ³, Stanislas Faguer ⁴, Antoine Huart ⁴, Mohamed Hamidou ⁵, Christian Agard ⁵, Bernard Bonnotte ⁶, Maxime Samson ⁷, Alexandre Karras ⁸, Noémie Jourde-Chiche ⁹, François Lifermann ¹⁰, Pierre Gobert ¹¹, Catherine Hanrotel-Saliou ¹², Pascal Godmer ¹³, Nicolas Martin-Silva ¹⁴, Grégory Pugnet ¹⁵, Marie Matignon ¹⁶, Olivier Aumaitre ¹⁷, Jean-François Viallard ¹⁸, François Maurier ¹⁹, Nadine Meaux Ruault ²⁰, Sophie Rivière ²¹, Jean Sibilia ²², Xavier Puéchal for the French Vasculitis Study Group ³, Luc Mouthon ³ and Loic Guillevin ³, ¹Institut Mutualiste Montsouris, Paris, France, ²APHP, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ⁴CHU Toulouse, Toulouse, France, ⁵CHU Nantes, Nantes, France, ⁶Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ⁷CHU Dijon, Dijon, France, ⁸Paris HEGP, Paris, France, ⁹APHM, Marseille, Marseille, France, ¹⁰CH Dax, Dax, France, ¹¹CH Avignon, Avignon, France, ¹²CHU Brest, Brest, France, ¹³CH Bretagne-Atlantique, Vannes, France, ¹⁴CHU Caen, Caen, France, ¹⁵CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, ¹⁶APHP, Créteil, France, ¹⁷CHU Clermont Ferrand, Clermont Ferrand, France, ¹⁸CHU Bordeaux, Bordeaux, France, ¹⁹Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ²⁰CHU Besançon, Besançon, France, ²¹CHU Montpellier, Montpellier, France, ²²CHU Strasbourg, Strasbourg, France
Background/Purpose: Rituximab (RTX) superiority over azathioprine to maintain ANCA-associated vasculitis (AAV) remission was demonstrated.The MAINRITSAN2 trial was designed to compare an individually tailored RTX-infusion schedule…
Abstract Number: 2627 • 2019 ACR/ARP Annual Meeting
Association of Work Productivity Assessed by Absenteeism and Presenteeism with Disease Activity, Damage and Health-related Quality of Life in Patients with ANCA-associated Vasculitis
Shinya Hirahara¹, Yasuhiro Katsumata ¹, Ken-ei Sada ², Hiroko Nagafuchi ³, Eiichi Tanaka ¹ and Masayoshi Harigai ¹, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kitaku, Okayama, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan
Background/Purpose: Chronic inflammatory diseases such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) substantially affects patients’ daily lives, including their ability to work. Although the management…
Abstract Number: 1665 • 2019 ACR/ARP Annual Meeting
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: AAV is a severe systemic vasculitis and rapid induction of remission is essential and high dose glucocorticoids (GC) are part of standard of care.…
Abstract Number: 2628 • 2019 ACR/ARP Annual Meeting
Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center
Marilia Dagostin¹, Sergio Nunes ², Samuel Shinjo ³ and Rosa Pereira ⁴, ¹University of Sao Paulo, São Paulo, Brazil, ²Univeristy Of Sao Paulo, São Paulo, ³Univeristy Of Sao Paulo, São Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Mortality of patients with ANCA-associated vasculitis (AAV) is higher than the general population. There are few papers in the literature regarding the factors associated…
Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…
Abstract Number: 2629 • 2019 ACR/ARP Annual Meeting
Urinary Inflammatory Cell Analysis Reflects the Renal Histopathology in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Yoko Wada¹, Masanori Sudo ², Takeshi Kuroda ³, Masaaki Nakano ⁴ and Ichiei Narita ², ¹Niigata Rinko Hospital, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ³Health administration office, Niigata University, Niigata, Niigata, Japan, ⁴School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Niigata, Japan
Background/Purpose: The anti-neutrophil cytoplasmic autoantibody (ANCA)- associated vasculitides (AAVs) include microscopic polyangiitis (MPA), granulomatosis with polyangitis (GPA), and eosinophilic granulomatosis with polyangitis (EGPA). These small-vessel…
Abstract Number: 1669 • 2019 ACR/ARP Annual Meeting
Comparison of Mizoribine with Azathioprine in Efficacy and Safety for ANCA-Associated Vasculitis
Sho Fukui ¹, Satoshi Kawaai¹, Genki Kidoguchi ¹, Takehiro Nakai ², Hiroki Ozawa ¹, Ayako Koido ¹, Yukihiko Ikeda ¹, Masei Suda ¹, Haruyuki Yanaoka ¹, Hisanori Shimizu ¹, Hiromichi Tamaki ¹, Tokutaro Tsuda ¹, Mitsumasa Kishimoto ³, Kenichi Yamaguchi ¹ and Masato Okada ¹, ¹St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Japan, ²St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan
Background/Purpose: Mizoribine (MZR) is an immunosuppressant working as an inhibitor of purine synthesis, which mechanism of action is similar to mycophenolate mofetil. MZR is approved…
Abstract Number: 2630 • 2019 ACR/ARP Annual Meeting
A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis
Ebru Dirikgil¹, Peter Verhoeven ², Sander Tas ³, Abraham Rutgers ⁴, Hein Bernelot Moens ⁵, Jacob van Laar ⁶, Willem Jan Bos ⁷ and Onno Teng ¹, ¹LUMC, Leiden, Netherlands, ²The Dutch Vasculitis Foundation, Silvolde, Netherlands, ³Amsterdam Rheumatology & immunology Center, Amsterdam UMC/University of Amsterdam, Amsterdam, Netherlands, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Ziekenhuisgroep Twente, Almelo, Netherlands, ⁶UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁷St. Antoniusziekenhuis, Nieuwegein, Netherlands
Background/Purpose: Several guidelines have been published on the diagnosis and treatment of anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV). These guidelines provide an evidence-based approach…
Abstract Number: 1670 • 2019 ACR/ARP Annual Meeting
Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)
Sohail Farshad¹, Alexandra Halalau ², Sayf Al-Katib ³, Julie George ⁴ and Elena Schiopu ⁵, ¹Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, ²Department of Internal Medicine, Beaumont Health System, Royal Oak, ³Department of Radiology, Beaumont Health System, Royal Oak, MI, ⁴Beaumont Health System, Royal Oak, MI, ⁵Department of Rheumatology, University of Michigan, Ann Arbor
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is the most prevalent adult vasculitis and is associated with significant inflammatory burden; chest computed tomography (CT)…
Abstract Number: 2632 • 2019 ACR/ARP Annual Meeting
Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center
Sana Afroz¹ and Najia Shakoor ², ¹RUMC, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: For years, cyclophosphamide (CYC) has been the primary treatment for severe anca-associated vasculitides (AAV) and has significantly improved disease related mortality. In addition, maintenance…
Abstract Number: 1672 • 2019 ACR/ARP Annual Meeting
Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018
Arielle Mendel¹, Simon Carette ² and Christian Pagnoux ², ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Mount Sinai Hospital and University Health Network, Toronto, ON, Canada
Background/Purpose: Rituximab (RTX) is an effective therapy for ANCA-Associated Vasculitis (AAV). The Canadian Vasculitis Research Network (CanVasc) recommends RTX for induction among patients with unacceptable risk…
Abstract Number: 2633 • 2019 ACR/ARP Annual Meeting
Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis
Audrey Hopkins¹, Stanley Chu ², Philip Seo ³, Eric Gapud ¹, Brendan Antiochos ¹, Shaker Eid ¹, Jason Liebowitz ¹ and Duvuru Geetha ¹, ¹Johns Hopkins Bayview Medical Center, Baltimore, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Induction regimens using either cyclophosphamide (CYC) or rituximab (RTX) have been shown to have similar efficacy and similar rates of adverse events in randomized…

« Previous Page
1
…
4
5
6
7
8
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].